Skip Navigation


Annals of Oncology Advance Access originally published online on April 28, 2005
Annals of Oncology 2005 16(7):1069-1075; doi:10.1093/annonc/mdi216
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
16/7/1069    most recent
mdi216v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (24)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Belani, C. P.
Right arrow Articles by Natale, R. B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Belani, C. P.
Right arrow Articles by Natale, R. B.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2005 European Society for Medical Oncology

Randomized phase III trial comparing cisplatin–etoposide to carboplatin–paclitaxel in advanced or metastatic non-small cell lung cancer

C. P. Belani1,*, J. S. Lee2, M. A. Socinski3, F. Robert4, D. Waterhouse5, K. Rowland6, R. Ansari7, R. Lilenbaum8 and R. B. Natale9

1 University of Pittsburgh Cancer Institute, Pittsburgh, PA; 2 MD Anderson Cancer Center, Houston, TX; 3 University of North Carolina, Chapel Hill, NC; 4 University of Alabama at Birmingham, Birmingham, AL; 5 Oncology/Hematology Care, Cincinnati, OH; 6 Carle Cancer Center, Urbana, IL; 7 Michiana Hematology/Oncology, South Bend, IN; 8 Mt. Sinai Comprehensive Cancer Center, Miami Beach, FL; 9 Cedars-Sinai Comprehensive Cancer Center, Los Angeles, CA, USA

* Correspondence to: Prof. C. P. Belani, University of Pittsburgh Cancer Institute, UPMC Cancer Pavilion, 150 Centre Avenue, Suite 570, Pittsburgh, PA 15232, USA. Tel: +1 412 648 6619; Fax +1 412 648 6579; Email: belanicp{at}upmc.edu

Background:: The present study was designed to evaluate the efficacy and safety of the regimen of carboplatin plus paclitaxel (investigational arm) versus the reference regimen of cisplatin plus etoposide for the treatment of advanced or metastatic non-small-cell lung cancer.

Patients and methods:: A total of 369 patients were enrolled, 179 on arm A (cisplatin 75 mg/m2 and etoposide 100 mg/m2) and 190 on arm B (carboplatin AUC=6 mg/ml min and paclitaxel 225 mg/m2), with cycles repeated every 3 weeks. The arms were well balanced with respect to age, performance status, weight loss, stage of disease and disease measurability. However, significantly more women were randomized to arm A than to arm B (P=0.039).

Results:: The objective response rate (ORR) was 15% on arm A compared with 23% on arm B (P=0.061). Median survival time, time to progression and 1-year survival rates for arms A and B were 274 days and 233 days (P=0.086), 111 days and 121 days (P=0.877), and 37% and 32%, respectively. The most prevalent toxicities were neutropenia and leukopenia and they occurred at a higher rate in arm A than in arm B.

Conclusion:: There was no statistically significant survival advantage for carboplatin–paclitaxel compared with cisplatin–etoposide. However, there was an overall benefit in quality of life with the carboplatin–paclitaxel regimen.

Key words: carboplatin, cisplatin, combination therapy, etoposide, non-small-cell lung cancer, paclitaxel


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Jpn J Clin OncolHome page
K. Naoki, H. Kunikane, T. Fujii, S. Tsujimura, N. Hida, H. Okamoto, and K. Watanabe
Dose-escalating and Pharmacokinetic Study of a Weekly Combination of Paclitaxel and Carboplatin for Inoperable Non-small Cell Lung Cancer: JCOG 9910-DI
Jpn. J. Clin. Oncol., June 10, 2009; (2009) hyp059v1.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Thorac. Surg.Home page
V. Steger, T. Walles, B. Kosan, T. Walker, T. Kyriss, S. Veit, J. Dippon, and G. Friedel
Trimodal Therapy for Histologically Proven N2/3 Non-Small Cell Lung Cancer: Mid-Term Results and Indicators for Survival.
Ann. Thorac. Surg., June 1, 2009; 87(6): 1676 - 1683.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
C. P. Belani, S. Ramalingam, M. C. Perry, R. V. LaRocca, D. Rinaldi, P. S. Gable, and W. J. Tester
Randomized, Phase III Study of Weekly Paclitaxel in Combination With Carboplatin Versus Standard Every-3-Weeks Administration of Carboplatin and Paclitaxel for Patients With Previously Untreated Advanced Non-Small-Cell Lung Cancer
J. Clin. Oncol., January 20, 2008; 26(3): 468 - 473.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
S. Ramalingam and C. Belani
Systemic Chemotherapy for Advanced Non-Small Cell Lung Cancer: Recent Advances and Future Directions
Oncologist, January 1, 2008; 13(suppl_1): 5 - 13.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
G. Simon, A. Sharma, X. Li, T. Hazelton, F. Walsh, C. Williams, A. Chiappori, E. Haura, T. Tanvetyanon, S. Antonia, et al.
Feasibility and Efficacy of Molecular Analysis-Directed Individualized Therapy in Advanced Non-Small-Cell Lung Cancer
J. Clin. Oncol., July 1, 2007; 25(19): 2741 - 2746.
[Abstract] [Full Text] [PDF]

Home page
 J. Thorac. Cardiovasc. Surg.Home page
H. Yokomise, M. Gotoh, T. Okamoto, Y. Yamamoto, S. Ishikawa, T. Nakashima, D. Masuya, D. Liu, and C.-l. Huang
Induction chemoradiotherapy (carboplatin-taxane and concurrent 50-Gy radiation) for bulky cN2, N3 non small cell lung cancer
J. Thorac. Cardiovasc. Surg., May 1, 2007; 133(5): 1179 - 1185.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
Y Ohe, Y Ohashi, K Kubota, T Tamura, K Nakagawa, S Negoro, Y Nishiwaki, N Saijo, Y Ariyoshi, M Fukuoka, et al.
Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small-cell lung cancer: Four-Arm Cooperative Study in Japan
Ann. Onc., February 1, 2007; 18(2): 317 - 323.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
R. Booton, P. Lorigan, H. Anderson, S. Baka, L. Ashcroft, M. Nicolson, M. O'Brien, D. Dunlop, K. O'Byrne, V. Laurence, et al.
A phase III trial of docetaxel/carboplatin versus mitomycin C/ifosfamide/cisplatin (MIC) or mitomycin C/vinblastine/cisplatin (MVP) in patients with advanced non-small-cell lung cancer: a randomised multicentre trial of the British Thoracic Oncology Group (BTOG1)
Ann. Onc., July 1, 2006; 17(7): 1111 - 1119.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
B. Besse, J. C. Soria, and T. Le Chevalier
Front-line doublets in advanced non-small cell lung cancer: The golden age for second line chemotherapy
Ann. Onc., July 1, 2005; 16(7): 997 - 998.
[Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.